Search

Displaying results 1021 - 1030 of 6831 in total
  1. Drug

    Timolol

    go.drugbank.com/drugs/DB00373
    ApprovedInvestigational

    [L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978. … Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.

    Mixtures: BIMAPROS T, LATAVITAL TProducts: T-LO
  2. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals. … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]

  3. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). … Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.

  4. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. … Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates

  5. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. … Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ).

  6. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

  7. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … [A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated.[A263211]

  8. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    However, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.

  9. Indication

    BCG-unresponsive non-muscle invasive bladder cancer

    go.drugbank.com/conditions/DBCOND0153568
    Drugs: Inbakicept · Nogapendekin alfa
    Synonyms: Non-muscle invasive bladder cancer ("nmibc") unresponsive/intolerant to bcg
  10. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. … Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate.